Tarsus Pharmaceuticals Stock Market Value
| TARS Stock | USD 63.22 0.29 0.46% |
| Symbol | Tarsus |
Is there potential for Pharmaceuticals market expansion? Will Tarsus introduce new products? Factors like these will boost the valuation of Tarsus Pharmaceuticals. If investors know Tarsus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Tarsus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share | Quarterly Revenue Growth 1.467 | Return On Assets | Return On Equity |
Understanding Tarsus Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Tarsus's accounting equity. The concept of intrinsic value - what Tarsus Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Tarsus Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tarsus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tarsus Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Tarsus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Tarsus Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Tarsus Pharmaceuticals.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Tarsus Pharmaceuticals on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Tarsus Pharmaceuticals or generate 0.0% return on investment in Tarsus Pharmaceuticals over 90 days. Tarsus Pharmaceuticals is related to or competes with Disc Medicine, Legend Biotech, Travere Therapeutics, Zai Lab, CG Oncology, Celcuity LLC, and Scholar Rock. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializati... More
Tarsus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Tarsus Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Tarsus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 12.48 | |||
| Value At Risk | (3.93) | |||
| Potential Upside | 3.78 |
Tarsus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tarsus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Tarsus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Tarsus Pharmaceuticals historical prices to predict the future Tarsus Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.23) |
Tarsus Pharmaceuticals February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 1.62 | |||
| Coefficient Of Variation | (2,321) | |||
| Standard Deviation | 2.29 | |||
| Variance | 5.26 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 12.48 | |||
| Value At Risk | (3.93) | |||
| Potential Upside | 3.78 | |||
| Skewness | 0.1371 | |||
| Kurtosis | 0.9461 |
Tarsus Pharmaceuticals Backtested Returns
Tarsus Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0408, which indicates the firm had a -0.0408 % return per unit of risk over the last 3 months. Tarsus Pharmaceuticals exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Tarsus Pharmaceuticals' Variance of 5.26, coefficient of variation of (2,321), and Risk Adjusted Performance of (0.02) to confirm the risk estimate we provide. The entity has a beta of 0.47, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tarsus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tarsus Pharmaceuticals is expected to be smaller as well. At this point, Tarsus Pharmaceuticals has a negative expected return of -0.0939%. Please make sure to validate Tarsus Pharmaceuticals' total risk alpha and day median price , to decide if Tarsus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.68 |
Very good reverse predictability
Tarsus Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between Tarsus Pharmaceuticals time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Tarsus Pharmaceuticals price movement. The serial correlation of -0.68 indicates that around 68.0% of current Tarsus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.68 | |
| Spearman Rank Test | -0.7 | |
| Residual Average | 0.0 | |
| Price Variance | 43.7 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.